Royalty Pharma
RPRX
363 hedge funds and large institutions have $8.74B invested in Royalty Pharma in 2023 Q4 according to their latest regulatory filings, with 79 funds opening new positions, 146 increasing their positions, 111 reducing their positions, and 29 closing their positions.
172% more first-time investments, than exits
New positions opened: 79 | Existing positions closed: 29
46% more call options, than puts
Call options by funds: $25.5M | Put options by funds: $17.5M
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
32% more repeat investments, than reductions
Existing positions increased: 146 | Existing positions reduced: 111
16% more funds holding
Funds holding: 313 → 363 (+50)
7% more capital invested
Capital invested by funds: $8.17B → $8.74B (+$575M)
2.91% more ownership
Funds ownership: 66.76% → 69.67% (+2.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
+$70.9M |
| 2 |
Amundi
Paris,
France
|
+$57.2M |
| 3 |
Swedbank
Stockholm,
Sweden
|
+$41.7M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$35M |
| 5 |
PCM
Patient Capital Management
Baltimore,
Maryland
|
+$34.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$67.3M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$62.4M |
| 3 |
Morgan Stanley
New York
|
-$48.9M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$39.6M |
| 5 |
Goldman Sachs
New York
|
-$36.8M |
RPRX Hedge Fund Activity: Q4 2023 in Review
363 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q4 2023, worth a combined $8.74B — up 7% from $8.17B a quarter earlier.
Buyers outnumbered sellers: 79 funds opened new RPRX positions and 29 closed out — a net gain of 50 holders — while 146 added to existing stakes and 111 trimmed.
The largest buyer was Man Group, opening a new position worth an estimated $70.9M. The largest seller was Aberdeen Group, cutting an estimated $67.3M.
- 363 institutional investors held Royalty Pharma (RPRX) as of Q4 2023, up from 313 in Q3 2023.
- Funds reported $8.74B of Royalty Pharma stock for Q4 2023, up 7% quarter-over-quarter.
- 79 funds opened new Royalty Pharma positions in Q4 2023 and 29 closed out, a net change of +50 holders.
- The largest Royalty Pharma buyer in Q4 2023 was Man Group, an estimated $70.9M added.
- The largest Royalty Pharma seller in Q4 2023 was Aberdeen Group, an estimated $67.3M sold.
Based on aggregated 13F filings for Q4 2023.